PTEN and cancer: In future, conditional tissue specific overexpression of Cryab and crossing of Cryab-conditional mouse line with other cancer-prone models such as KrasG12D expression, PTEN and/or p53 loss will allow detailed mechanistic evaluation of its function in a given cancer type.